Abstract
Radiofrequency ablation (RFA) has a high local control rate for lesions < 4 cm; however, it is limited in the treatment of larger tumors, in part due to tumor blood flow that dissipates local heat and limits ablation diameter. Reducing tumor blood flow prior to RFA may increase ablation diameter and improve treatment outcomes in patients with lesions > 4 cm. It has been previously shown that a systemic antiangiogenic agent can improve tumor ablation but the optimum timing between applying antiangiogenic therapy and ablation is unknown.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
